口服生技药品市场：依药物类别、适应症、依配销通路、按地区

Oral Biologics Market, By Drug Class, By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome & Chronic Idiopathic Constipation, Others ), By Distribution channel, By Geography

出版日期: 2023年08月31日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2023 年，全球口服生技药品市场规模将达到 26.2 亿美元，预计在预测期内（2023-2030 年）年复合成长率为 35.4%。

报告范围		报告详情
基准年	2022年	2023年市场规模	26.2亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	35.40%	2030年市场规模预测	218.4亿美元

口服生技药品全球市场占有率(%)（以药物类型），2023 年

口服生技药品是指具有生物来源的一类药物，例如蛋白质或抗体，并且给药口服（以锭剂或胶囊的形式）而不是透过注射给药。由于其具有改变各种治疗领域的治疗格局的潜力，该领域正在吸引大量关注和投资。口服生技药品的潜在用途涵盖广泛的治疗领域。类风湿性关节炎、发炎性肠道疾病疾病和多发性硬化症等自体自体免疫疾病是主要目标之一。此外，口服生技药品还有望治疗糖尿病、癌症和罕见遗传疾病。这种用途吸引了製药巨头和新兴企业的关注，形成了促进市场创新和协作的竞争形势。此外，患者便利性和技术进步使口服生技药品成为传统注射生技药品的有前途的替代品，预计将在预测年度内推动市场成长。

市场动态

主要市场参与企业正专注于在市场上推出新产品，以扩大其全球业务，预计这将在预测期内推动市场成长。例如，2022年1月，全球製药公司诺和诺德推出了口服锭剂GLP-1受体类似物（GLP-1 RA），用于治疗糖尿病。在口服 GLP-1 受体类似物 (GLP-1 RA)锭剂发布之前，GLP-1 受体类似物 (GLP-1 RA) 仅以注射剂形式提供。 GLP-1 RA从未被製成口服药物。口服索马鲁肽是GLP-1RA索马鲁肽和吸收促进剂SNAC的复合製剂，可防止其像其他胜肽一样在胃中分解并改善吸收。

本研究的主要特点

本报告详细分析了全球口服生技药品市场，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率(CAGR)。它揭示了各个细分市场的潜在商机，并解释了市场有吸引力的投资提案矩阵。
它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球口服生技药品市场的主要企业。
该报告的见解将使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出资讯的决策。
口服生技药品全球市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过分析全球口服生技药品市场时所使用的各种策略矩阵来促进决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 2.62 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	35.40%	2030 Value Projection:	US$ 21.84 Bn

Oral biologics refers to a category of medications that are biologically derived, like proteins or antinodies, and are administered orally (in the form of pills and capsules) rather than through injections. This segment has garnered significant attention and investment due to its potential to revolutionize the treatment landscape across various therapeutic areas. The potential applications of oral biologics span a wide range of therapeutic areas. Autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, are among the prominent targets. Additionally, oral biologics hold promise for treating diabetes, cancer, and rare genetic diseases. This versatility has attracted attention from both pharmaceutical giants and innovative startups, fostering a competitive landscape that drives innovation and collaboration in the market. Further, patient convenience and technological advancements have positioned oral biologics as a promising alternative to traditional injectable biologics, which is expected to drive market growth in the forecast years.

Market Dynamics

The key market players are focused on the launch of new products in the market to expand their business globally, and this is expected to boost the growth of the market over the forecast period. For instance, in January 2022, Novo Nordisk, a global pharmaceutical company, launched the GLP-1 receptor analogue (GLP-1 RA) in an oral pill formulation for the treatment of diabetes. Before the launch of the GLP-1 receptor analogue (GLP-1 RA) oral pill, GLP-1 receptor analogue (GLP-1 RA) was only available in injection form. A GLP-1 RA has never before been created in an oral formulation. In order to prevent it from degrading in the stomach like other peptides do and to improve absorption, oral semaglutide is a co-formulation of GLP-1RA semaglutide and the absorption enhancer SNAC.

Key features of the study:

This report provides an in-depth analysis of the global oral biologics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global oral biologics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market.

Oral Biologics Market Detailed Segmentation:

By Drug Class:
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Others
By Disease Indication:
- Diabetes
- Hyperoxaluria
- Acromegaly
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
By Distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Novo Nordisk A/S
- Biocon Limited
- Oramed Pharmaceuticals, Inc.
- Rani Therapeutics
- Entera Bio Ltd.
- AbbVie Inc.
- Enteris BioPharma, Inc.
- Chiasma, Inc.
- Allena Pharmaceuticals, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Oral Biologics Market-COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Oral Biologics Market, By Drug Class, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Recombinant Enzyme
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Guanylate Cyclase-C Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Somatostatin Analogue
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Oral Biologics Market, By Disease Indication, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Hyperoxaluria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Acromegaly
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Oral Biologics Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Oral Biologics Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa